Immune Response on Neoadjuvant Therapy in Non-small-cell Lung Cancer (NSCLC)
Status:
Completed
Trial end date:
2011-06-01
Target enrollment:
Participant gender:
Summary
Primary objective is to assess the overall response rate (ORR) after induction therapy with
docetaxel in combination with CDDP and cetuximab in patients with NSCLC stage IB, II, and
IIIa. ORR will be determined by the percentage of patients achieving objective response rates
(CR + PR) according to the RECIST guidelines.